Replies to post #3500 on Antares Pharma, Inc. (ATRS)

[Bio_pete]

"SQ MTX market exclusivity"


A company could potentially have filed for ANDA approval of a basic pre-filled MTX syringe without investors being aware. The company has always said this was not a competitive threat.